ARWR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

244.84M

+9693.67%

-0.096

-93.11%

58.94M

-89.14%

-1.083

-139.38%

-1.333

+5.78%

Estimates Revision

The market is revising Upward the revenue expectations for Arrowhead Pharmaceuticals, Inc. (ARWR) for FY2026, with the revenue forecasts being adjusted by 12.2% over the past three months. During the same period, the stock price has changed by 80.26%.

Revenue Estimates for FY2026

Revise Upward

+12.2%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+2.5%

In Past 3 Month

Stock Price

Go Up

+80.26%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 61.63 USD with a low forecast of 48.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

48.00

Averages

61.63

High

85.00

Current: 0.000

Low

48.00

Averages

61.63

High

85.00

Goldman Sachs

Andrea Newkirk

Neutral

maintain

$50 -> $85

2026-01-07

New

Reason

Goldman Sachs

Andrea Newkirk

Price Target

$50 -> $85

2026-01-07

New

maintain

Neutral

Reason

Goldman Sachs analyst Andrea Newkirk raised the firm's price target on Arrowhead (ARWR) to $85 from $50 and keeps a Neutral rating on the shares. Arrowhead released early clinical data from its RNAi obesity therapies, ARO-INHBE and ARO-ALK7, with ARO-INHBE combined with Eli Lilly's (LLY) tirzepatide showing superior weight loss and body composition improvements versus monotherapy, supporting a multi-modality approach for patients less responsive to GLP-1 treatments, while ARO-ALK7 provided first evidence of successfully targeting an adipocyte-expressed gene with potential implications for other cardiometabolic targets, the analyst tells investors in a research note.

Chardan

NULL -> Buy

upgrade

$60 -> $80

2026-01-07

New

Reason

Chardan

Price Target

$60 -> $80

2026-01-07

New

upgrade

NULL -> Buy

Reason

Chardan raised the firm's price target on Arrowhead to $80 from $60 and keeps a Buy rating on the shares. The company reported "encouraging" initial interim data from the Phase I/IIa trials for its two siRNA obesity candidates, ARO-INHBE and ARO-ALK7, the analyst tells investors in a research note.

Morgan Stanley

Equal Weight

maintain

$48 -> $81

2026-01-07

New

Reason

Morgan Stanley

Price Target

$48 -> $81

2026-01-07

New

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Arrowhead to $81 from $48 and keeps an Equal Weight rating on the shares. Early ARO-INHBE and ARO-ALK7 monotherapy data provide further validation of a target for fat loss and highlight potential in obesity, the analyst tells investors. The firm views early data as "promising," with potential for obesity to emerge as another key value driver, the analyst added.

H.C. Wainwright

Buy

maintain

2026-01-06

New

Reason

H.C. Wainwright

Price Target

2026-01-06

New

maintain

Buy

Reason

After Arrowhead Pharmaceuticals released initial Phase 1/2a data for ARO-INHBE and ARO-ALK7, with both programs demonstrating significant fat reduction, H.C. Wainwright says these data provide "a significant validation" of TRiM, Arrowhead's RNA interference platform, and de-risk Arrowhead's obesity franchise. The firm reiterates its Buy rating on Arrowhead shares.

Clear Street

Bill Maughan

Buy

maintain

$47

2026-01-06

New

Reason

Clear Street

Bill Maughan

Price Target

$47

2026-01-06

New

maintain

Buy

Reason

Clear Street analyst Bill Maughan says Wave Life Sciences (WVE) is trading higher after Arrowhead (ARWR) reported the first clinical weight loss data for its RNAi-based obesity candidates targeting INHBE or its receptor, ALK7. Wave's December data support the INHBE-targeting mechanism for the improvement in cardiometabolic health by reducing fat, including visceral fat, and Arrowhead's data "go a step further: by combining with a GLP-1, and showed additive weight loss, the analyst tells investors in a research note. Clear believes the INHBE-targeting is delivering fat reduction and muscle growth, which i an additive benefit over GLP-1s, a safe profile, along with infrequent dosing. The firm maintains a Buy rating on Wave Life Sciences with a $47 price target.

Bernstein

Market Perform

upgrade

$17 -> $35

2025-12-31

Reason

Bernstein

Price Target

$17 -> $35

2025-12-31

upgrade

Market Perform

Reason

Bernstein raised the firm's price target on Arrowhead (ARWR) to $35 from $17 and keeps a Market Perform rating on the shares. The firm notes Arrowhead is holding an investor event on Tuesday, January 6 to share initial data from its obesity drugs ARO-INHBE and ARO-ALK7. Bernstein believes investors will be most focused on the comparison to Wave Life Sciences (WVE) in INHBE mono; incremental total weight loss impact on top of tirzepatide in the INHBE combo cohorts; and ALK7 target engagement and safety.

Valuation Metrics

The current forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR.O) is -21.43, compared to its 5-year average forward P/E of -25.74. For a more detailed relative valuation and DCF analysis to assess Arrowhead Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-25.74

Current PE

-21.43

Overvalued PE

6.52

Undervalued PE

-58.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-28.82

Current EV/EBITDA

-35.12

Overvalued EV/EBITDA

5.36

Undervalued EV/EBITDA

-63.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

23.92

Current PS

22.22

Overvalued PS

37.24

Undervalued PS

10.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ARWR News & Events

Events Timeline

No data

News

8.5

01-08Businesswire

PinnedArrowhead Pharmaceuticals Prices $625M Convertible Notes and 3.1M Shares Offering

5.0

01-07Businesswire

Arrowhead Secures NMPA Approval for REDEMPLO to Treat High Triglycerides in China

8.5

01-06Businesswire

Arrowhead Pharmaceuticals Plans $500M Convertible Notes and $200M Stock Offering

People Also Watch

Frequently Asked Questions

What is Arrowhead Pharmaceuticals Inc (ARWR) stock price today?

The current price of ARWR is 65 USD — it has decreased -1.05 % in the last trading day.

What is Arrowhead Pharmaceuticals Inc (ARWR)'s business?

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

What is the price predicton of ARWR Stock?

What is Arrowhead Pharmaceuticals Inc (ARWR)'s revenue for the last quarter?

Arrowhead Pharmaceuticals Inc revenue for the last quarter amounts to 256.47M USD, decreased % YoY.

What is Arrowhead Pharmaceuticals Inc (ARWR)'s earnings per share (EPS) for the last quarter?

Arrowhead Pharmaceuticals Inc. EPS for the last quarter amounts to -0.17 USD, decreased -87.59 % YoY.

What changes have occurred in the market's expectations for Arrowhead Pharmaceuticals Inc (ARWR)'s fundamentals?

How many employees does Arrowhead Pharmaceuticals Inc (ARWR). have?

Arrowhead Pharmaceuticals Inc (ARWR) has 711 emplpoyees as of January 09 2026.

What is Arrowhead Pharmaceuticals Inc (ARWR) market cap?

Today ARWR has the market capitalization of 8.83B USD.